Home / Business and Economy / Neurocrine Set for $6B+ Revenue by 2031 on New Drugs
Neurocrine Set for $6B+ Revenue by 2031 on New Drugs
25 Oct
Summary
- Neurocrine's Q2 revenue increased 39% year-over-year to $959 million.
- Ingrezza sales rose 15% to $716 million, with newer drugs adding $1 billion.
- Company projects over $6 billion in annual revenue by 2031.
Neurocrine Biosciences achieved a remarkable 39% year-over-year revenue surge in Q2 2026, totaling $959 million. This growth was propelled by its established drug Ingrezza, which saw a 15% sales increase to $716 million and has seen its full-year forecast raised. The company is also benefiting from two newer drugs, Crenessity and Vykat XR, which combined are generating over $1 billion in annualized revenue.
Looking ahead, Neurocrine is poised for significant expansion, with projections indicating annual revenues could surpass $6 billion by 2031. This optimistic outlook hinges on the continued success of Ingrezza, the expanded adoption of its newer therapies, and the potential commercialization of pipeline candidates. Key clinical trial results for depression and schizophrenia treatments are expected in 2027, representing crucial future growth drivers.
The company's Q2 profitability, with net income around $144 million, provides a strong foundation for ongoing research and development. Despite potential challenges like competition for Ingrezza, clinical trial risks, and pricing pressures, Neurocrine's diversified portfolio and promising pipeline suggest a trajectory toward becoming a substantially larger neuroscience-focused pharmaceutical entity.
